Centre for Endocrinology, Diabetes, and Metabolism, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham B15 2TT, United Kingdom.
J Clin Endocrinol Metab. 2012 Mar;97(3):E465-75. doi: 10.1210/jc.2011-2413. Epub 2011 Dec 14.
Isolated 17,20 lyase deficiency is commonly defined by apparently normal 17α-hydroxylase activity but severely reduced 17,20 lyase activity of the bifunctional enzyme cytochrome P450 (CYP) enzyme 17A1 (CYP17A1), resulting in sex steroid deficiency but normal glucocorticoid and mineralocorticoid reserve. Cytochrome b5 (CYB5A) is thought to selectively enhance 17,20 lyase activity by facilitating the allosteric interaction of CYP17A1 with its electron donor P450 oxidoreductase (POR).
We investigated a large consanguineous family including three siblings with 46,XY disorder of sex development (DSD) presenting with isolated 17,20 lyase deficiency.
We investigated the clinical and biochemical phenotype, conducted genetic analyses, and functionally characterized the identified CYB5A mutation in cell-based CYP17A1 coexpression assays.
All three siblings presented with 46,XY DSD, sex steroid deficiency, normal mineralocorticoids and glucocorticoids, and a urine steroid metabolome suggestive of isolated 17,20 lyase deficiency. CYP17A1 and POR sequences were normal, but we detected a homozygous CYB5A missense mutation (g.28,400A→T; p.H44L). Functional in vitro analysis revealed normal CYP17A1 17α-hydroxylase activity but severely impaired 17,20 lyase activity. In silico analysis suggested the disruption of CYB5A heme binding by p.H44L.
We have identified the first human CYB5A missense mutation as the cause of isolated 17,20 lyase deficiency in three individuals with 46,XY DSD. Detailed review of previously reported cases with apparently isolated 17,20 lyase deficiency due to mutant CYP17A1 and POR reveals impaired 17α-hydroxylase activity as assessed by steroid metabolome analysis and short cosyntropin testing. This suggests that truly isolated 17,20 lyase deficiency is observed only in individuals with inactivating CYB5A mutations.
孤立型 17,20 裂合酶缺乏症通常定义为明显正常的 17α-羟化酶活性,但双功能酶细胞色素 P450(CYP)酶 17A1(CYP17A1)的 17,20 裂合酶活性严重降低,导致性激素缺乏,但糖皮质激素和盐皮质激素储备正常。细胞色素 b5(CYB5A)被认为通过促进 CYP17A1 与其电子供体 P450 氧化还原酶(POR)的变构相互作用,选择性地增强 17,20 裂合酶活性。
我们研究了一个大型近亲家族,包括三个患有 46,XY 性发育障碍(DSD)的兄弟姐妹,他们表现出孤立型 17,20 裂合酶缺乏症。
我们研究了临床和生化表型,进行了基因分析,并在细胞 CYP17A1 共表达测定中对鉴定出的 CYB5A 突变进行了功能表征。
所有三个兄弟姐妹均表现出 46,XY DSD、性激素缺乏、正常的盐皮质激素和糖皮质激素,以及尿液类固醇代谢组学提示孤立型 17,20 裂合酶缺乏症。CYP17A1 和 POR 序列正常,但我们检测到纯合 CYB5A 错义突变(g.28,400A→T;p.H44L)。体外功能分析显示正常的 CYP17A1 17α-羟化酶活性,但严重损害 17,20 裂合酶活性。计算机分析提示 p.H44L 破坏了 CYB5A 的血红素结合。
我们已经确定了第一个人类 CYB5A 错义突变是三个 46,XY DSD 个体中孤立型 17,20 裂合酶缺乏症的原因。对先前报道的由于突变型 CYP17A1 和 POR 导致的明显孤立型 17,20 裂合酶缺乏症的病例进行详细回顾,发现通过类固醇代谢组分析和短促肾上腺皮质激素测试评估的 17α-羟化酶活性受损。这表明只有在具有失活 CYB5A 突变的个体中才会观察到真正的孤立型 17,20 裂合酶缺乏症。